Loading
ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type.
CIViC holds 9 clinical evidence items and 0 assertions across 3 variants, naming Doxorubicin, Salinomycin, Gemcitabine and Cytarabine and others. IntOGen calls it a driver in 6 cohorts (5 activating, 1 loss-of-function), covering Glioblastoma Multiforme, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Plasma Cell Myeloma, Small Cell Lung Cancer.
In plain words · ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression.
No product in this corpus aims at ZEB1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ZEB1: RNA low tissue specificity; high antibody staining in 12 normal tissues; highest cancer staining glioma (6 of 12 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma, Lymphoma, Lung cancer (all types), Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P37275; CIViC gene ZEB1; IntOGen ZEB1; Human Protein Atlas ZEB1 tissue; Open Targets ENSG00000148516 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Williams T.M. et al, Science, 1991, "Identification of a zinc finger protein that inhibits IL-2 gene expression". Source.
Sources: HGNC HGNC:11642 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P37275 (protein name, function text, keywords and locations (REST API)); CIViC gene ZEB1 (9 evidence items, 0 assertions, 3 variants; diseases: Mantle Cell Lymphoma, Colon Cancer, Cancer (GraphQL API, CC0)); IntOGen ZEB1 (driver in 6 cohorts (Act 5, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Location: Nucleus (UniProt). Locus 10p11.22 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Caudate, Hippocampus, Ovary, Soft tissue.
RNA cancer enhanced: Glioblastoma Multiforme 37 pTPM.
Medium only: liver cancer, renal cancer, testis cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ZEB1" OR ABSTRACT:"ZEB1" OR TITLE:"zinc finger E-box binding homeobox 1" OR ABSTRACT:"zinc finger E-box binding homeobox 1" OR TITLE:"Zinc finger E-box-binding homeobox 1" OR ABSTRACT:"Zinc finger E-box-binding homeobox 1" OR TITLE:"AREB6" OR ABSTRACT:"AREB6" OR TITLE:"NIL-2-A" OR ABSTRACT:"NIL-2-A" OR TITLE:"Zfhep" OR ABSTRACT:"Zfhep") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZEB1, not a curated reading list.
Shares Invasion: proteases, adhesion & the invasive front, Glioma & glioblastoma, CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, IntOGen, Multiple myeloma, Colorectal cancer.
Shares Nasopharyngeal carcinoma, CIViC, IntOGen, Colorectal cancer.
Shares Invasion: proteases, adhesion & the invasive front, CIViC.
Shares Epithelial-mesenchymal transition & drug efflux, CIViC, Non-small-cell lung cancer.
Shares Nasopharyngeal carcinoma, IntOGen.
Shares Nasopharyngeal carcinoma, IntOGen.
Shares Nasopharyngeal carcinoma, IntOGen.